{"id":"W4321374071","doi":"10.1161/circulationaha.121.057844","title":"Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors","year":2023,"lang":"en","type":"article","venue":"Circulation","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Thomas Hospital; University of Calgary; SickKids Foundation; McMaster University; Population Health Research Institute","funders":"CytoSorbents Europe; LEO Pharma; Swedish Orphan Biovitrum; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Pfizer Canada; Alexion Pharmaceuticals; Novo Nordisk; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Bayer; Servier; Pfizer","keywords":"Medicine; Rivaroxaban; Apixaban; Edoxaban; Internal medicine; Population; Major bleeding; Hemostasis; Atrial fibrillation; Anesthesia; Surgery; Warfarin","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009456899,0.0008910304,0.001036647,0.0006274694,0.0006261918,0.001771197,0.000770473,0.00133136,0.02165587],"category_scores_gemma":[0.01642473,0.000389768,0.001594331,0.0006043928,0.0001955505,0.0005558973,0.0007281035,0.00102449,0.008930512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006266497,"about_ca_system_score_gemma":0.00299732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001262008,"about_ca_topic_score_gemma":0.001499659,"domain_scores_codex":[0.993573,0.002801098,0.001222503,0.0007621253,0.001336028,0.0003053667],"domain_scores_gemma":[0.9857738,0.00358763,0.001512702,0.00149172,0.006088723,0.00154537],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1215952,0.004678892,0.06983317,0.009662085,0.007227057,0.001699791,0.0005232205,0.000515023,0.005788144,0.002196214,0.5955921,0.1806893],"study_design_scores_gemma":[0.05033348,0.02315757,0.05434567,0.001741539,0.004692601,0.001506411,0.0001856166,0.0004035377,0.002953239,0.0007954253,0.8598144,0.00007049218],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"dataset","genre_gemma":"empirical","genre_scores_codex":[0.2623115,0.03972708,0.01565634,0.02813149,0.03171947,0.06897724,0.3966431,0.001164949,0.1556689],"genre_scores_gemma":[0.5098763,0.02112734,0.01930806,0.0474667,0.01867138,0.04381637,0.2581716,0.0008654365,0.08069686],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02165587,"threshold_uncertainty_score":0.07244605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1266245444366116,"score_gpt":0.3600261947670884,"score_spread":0.2334016503304768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}